We tested a number of different targeted drugs (PI3K: alpelisib (BYL719), buparlisib (BKM120) and IPI549; AKT: Ipatasertib (GDC-0068); mTOR: rapamycin) for their effects on T47D breast cancer cells (Fig. 5). Here, MTOR is linked to breast carcinoma.